Price T Rowe Associates Inc. MD Sells 233,841 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Price T Rowe Associates Inc. MD lowered its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 8.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,402,452 shares of the company's stock after selling 233,841 shares during the quarter. Price T Rowe Associates Inc. MD owned about 2.36% of Dyne Therapeutics worth $56,603,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in DYN. KBC Group NV boosted its stake in shares of Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company's stock worth $74,000 after purchasing an additional 978 shares during the period. Summit Investment Advisors Inc. boosted its holdings in shares of Dyne Therapeutics by 9.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock valued at $203,000 after purchasing an additional 721 shares during the period. KLP Kapitalforvaltning AS bought a new position in Dyne Therapeutics in the fourth quarter worth approximately $257,000. Magnetar Financial LLC bought a new stake in Dyne Therapeutics during the fourth quarter valued at about $263,000. Finally, E Fund Management Co. Ltd. lifted its holdings in shares of Dyne Therapeutics by 11.8% during the 4th quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock valued at $279,000 after purchasing an additional 1,249 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.

Insider Buying and Selling

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the sale, the insider now directly owns 199,087 shares of the company's stock, valued at $2,777,263.65. The trade was a 1.29 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. In the last three months, insiders sold 6,237 shares of company stock valued at $77,760. 20.77% of the stock is owned by corporate insiders.

Analyst Ratings Changes

DYN has been the topic of several analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $46.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 17th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $45.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Piper Sandler cut their price target on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Scotiabank initiated coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price target for the company. Finally, JPMorgan Chase & Co. dropped their price target on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a research report on Friday, March 21st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $47.46.

Dyne Therapeutics Price Performance

Shares of DYN stock traded down $0.13 during trading hours on Friday, reaching $11.86. 1,040,609 shares of the company were exchanged, compared to its average volume of 1,555,082. The stock's fifty day moving average is $10.62 and its two-hundred day moving average is $19.13. The company has a market cap of $1.35 billion, a price-to-earnings ratio of -3.33 and a beta of 1.21. Dyne Therapeutics, Inc. has a fifty-two week low of $6.36 and a fifty-two week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.04. On average, research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.